QPPV.COM KNOWLEDGE ASSESSMENT

Pozelimab: Classification, Mechanism and Pharmacovigilance

Test your understanding of the concepts covered by Pozelimab: Classification, Mechanism and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 All ten participants met the composite primary endpoint at week 24. What is the most defensible interpretation?

The result proves that every treated patient in routine practice will respond. The result is an observed outcome in a very small single-arm study, not a precise estimate of comparative effect. The result establishes that pozelimab is superior to every alternative treatment. The result can be disregarded because the study did not include a concurrent control group.

Question 2 of 10 A team outside the United States is considering use of the U.S. dosing schedule described in the article. What is the most appropriate regulatory approach?

Apply it automatically because FDA authorisation establishes the regimen internationally. Use it only if the pivotal trial was conducted in that jurisdiction. Check the current product information and requirements applicable in that jurisdiction. Assume the U.S. schedule applies unless a local authority has specifically prohibited it.

Question 3 of 10 A patient’s CHAPLE symptoms recur after a delayed dose. Which initial assessment is most appropriate?

Classify the recurrence as confirmed pharmacologic failure based on symptoms alone. Review dose history, disease measures, intercurrent illness and alternative explanations before concluding treatment failure. Exclude a relationship to treatment because the patient has an inherited disease. Assume the recurrence is an adverse drug reaction and stop evaluating disease activity.

Question 4 of 10 How should spontaneous reports and carefully followed real-world cases contribute to safety evaluation for pozelimab?

They can add information about rare events and longer-term exposure, but individual reports cannot estimate incidence on their own. They replace the need for clinical-study data because they include routine practice. They establish the incidence of an adverse reaction whenever several similar reports are received. They are useful only when the pivotal trial included a large concurrent control group.

Question 5 of 10 Which statement best characterises the pivotal phase 2/3 evidence?

A large randomised trial demonstrated a precise comparative effect against concurrent controls. An open-label, single-arm study of ten patients used a historical control context. A placebo-controlled trial enrolled ten thousand participants. A registry study established long-term incidence rates for uncommon adverse reactions.

Question 6 of 10 A patient experiences symptoms after administration, and a delayed immune-complex phenomenon is also being considered. Which approach best supports assessment?

Classify every post-dose symptom as an immediate hypersensitivity reaction. Distinguish immediate infusion or injection reactions from delayed symptoms and immune-complex phenomena, documenting timing and objective features. Classify delayed symptoms as unrelated because they did not occur during administration. Record only the treatment given, without the route or timing of symptoms.

Question 7 of 10 For a serious suspected infection in a patient receiving pozelimab, which case documentation is most complete?

Record only the diagnosis and whether the patient was vaccinated. Record onset relative to exposure, microbiology and serogroup if known, vaccination dates, prophylaxis, treatment, outcome and any treatment interruption with its reason. Record only whether the patient recovered, because exposure details are available from the prescription. Record the suspected organism but omit negative tests and treatment history.

Question 8 of 10 What is the most appropriate interpretation of a delay or interruption in pozelimab treatment?

It is clinically irrelevant because C5 inhibition permanently corrects CD55 deficiency. It may matter clinically because treatment suppresses terminal complement activity while it is being given, so exposure timing should be reviewed. It proves that any subsequent symptom is caused by withdrawal. It eliminates the need to assess infection or disease activity.

Question 9 of 10 Which clinical and regulatory statement about the U.S. authorisation is accurate according to the article?

Pozelimab is FDA-authorised for all forms of protein-losing enteropathy in adults. Pozelimab is FDA-authorised for CD55-deficient PLE/CHAPLE in adults and children aged 1 year and older. Pozelimab is FDA-authorised for CHAPLE only in children older than 12 years. Pozelimab is FDA-authorised for inherited complement disorders generally, regardless of diagnosis.

Question 10 of 10 Which vaccination strategy is specified in the U.S. label as summarised in the article?

Vaccination against meningococcal serogroups A, C, W and Y and serogroup B before treatment when feasible. Vaccination against serogroup B alone, because other serogroups are not relevant. Vaccination against all bacterial pathogens before treatment, with no meningococcal-specific recommendation. No vaccination is recommended because C5 inhibition prevents vaccine responses.

Pozelimab: Classification, Mechanism and Pharmacovigilance

Cookie Settings